Grantham Mayo Van Otterloo & Co. LLC Sells 91,273 Shares of CVS Health Corporation $CVS

Grantham Mayo Van Otterloo & Co. LLC trimmed its holdings in CVS Health Corporation (NYSE:CVS) by 10.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 760,952 shares of the pharmacy operator’s stock after selling 91,273 shares during the period. Grantham Mayo Van Otterloo & Co. LLC owned approximately 0.06% of CVS Health worth $57,368,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in CVS. Norges Bank bought a new position in shares of CVS Health in the second quarter worth $1,358,698,000. Invesco Ltd. raised its stake in shares of CVS Health by 15.3% during the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares during the period. Vanguard Group Inc. lifted its holdings in CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in CVS Health by 153.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator’s stock worth $214,240,000 after purchasing an additional 1,878,217 shares during the period. Finally, Panagora Asset Management Inc. grew its holdings in CVS Health by 2,675.7% during the 2nd quarter. Panagora Asset Management Inc. now owns 1,116,742 shares of the pharmacy operator’s stock valued at $77,033,000 after buying an additional 1,076,509 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 1.0%

NYSE CVS opened at $77.91 on Friday. The stock has a 50-day moving average of $78.49 and a 200-day moving average of $77.60. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $85.15. The firm has a market cap of $99.12 billion, a PE ratio of 56.46, a price-to-earnings-growth ratio of 0.81 and a beta of 0.49.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The business’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, sell-side analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s dividend payout ratio is presently 192.75%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare’
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing – Here’s Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health (NYSE:CVS) Price Target to $97.00

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein restated a “market perform” rating and issued a $91.00 price objective on shares of CVS Health in a research report on Tuesday, January 6th. UBS Group reiterated an “outperform” rating on shares of CVS Health in a research note on Wednesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Argus dropped their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, January 28th. Finally, Wells Fargo & Company decreased their target price on CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 13th. Nineteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.91.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.